Search

Your search keyword '"LYSINE specific demethylase 1"' showing total 272 results

Search Constraints

Start Over You searched for: Descriptor "LYSINE specific demethylase 1" Remove constraint Descriptor: "LYSINE specific demethylase 1"
272 results on '"LYSINE specific demethylase 1"'

Search Results

1. Lysine specific demethylase 1 inhibits sodium arsenite activation of HSCs by regulating SESN2/AMPK/ULK1 signaling pathway activity.

2. Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib

3. 中低强度运动干预高脂饲养小鼠膝关节损伤软骨细胞 LncRNA HOTAIR 的表达.

4. GFI1B and LSD1 repress myeloid traits during megakaryocyte differentiation.

5. Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib.

6. LSD1 inhibition modulates transcription factor networks in myeloid malignancies.

7. Chemical modulation of Schistosoma mansoni lysine specific demethylase 1 (SmLSD1) induces wide-scale biological and epigenomic changes [version 1; peer review: 2 approved]

8. Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer.

9. Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma.

10. PHF21A Related Disorder: Description of a New Case.

11. Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

12. Repurposing antidepressants for anticancer drug discovery.

13. Evolution Increases Primates Brain Complexity Extending RbFOX1 Splicing Activity to LSD1 Modulation.

14. Histone demethylase LSD1 regulates lipid homeostasis duringCryptococcus neoformans infection.

15. 'Adding new Molecular Insights to a given Endophenotype: the Relevance of Epigenetics in Environmental Stress Response'

16. Exploring cyclopropylamine containing cyanopyrimidines as LSD1 inhibitors: Design, synthesis, ADMET, MD analysis and anticancer activity profiling.

17. ORY‐1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor.

18. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

19. Histone demethylase Lsd1 is required for the differentiation of neural cells in Nematostella vectensis.

20. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.

21. Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer.

22. Dual targeting of KDM1A and antioxidants is an effective anticancer strategy.

23. Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins.

24. Unveiling Arformoterol as a potent LSD1 inhibitor for breast cancer treatment: A comprehensive study integrating 3D-QSAR pharmacophore modeling, molecular docking, molecular dynamics simulations and in vitro assays.

25. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein.

26. Natural products as LSD1 inhibitors for cancer therapy.

27. Data on Biology Described by Researchers at Radboud University Medical Center (GFI1B and LSD1 repress myeloid traits during megakaryocyte differentiation).

28. Researchers from Hamadan University of Medical Sciences Describe Findings in Breast Cancer (Unveiling Arformoterol As a Potent Lsd1 Inhibitor for Breast Cancer Treatment: a Comprehensive Study Integrating 3d-qsar Pharmacophore Modeling,...).

29. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors.

30. Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch.

31. Characterization of imine reductases in reductive amination for the exploration of structure-activity relationships.

33. SRF and SRFΔ5 Splicing Isoform Recruit Corepressor LSD1/KDM1A Modifying Structural Neuroplasticity and Environmental Stress Response.

34. HFIP‐Promoted de Novo Synthesis of Biologically Relevant Nonnatural α‐Arylated Amino Esters and Dipeptide Mimetics.

35. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer.

36. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies.

37. Conversion of human fibroblasts into multipotent cells by cell-penetrating peptides.

38. LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.

39. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).

40. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.

41. 木兰花碱减轻慢性应激小鼠抑郁样行为及对脑部LSD1组蛋白修饰的影响.

42. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.

43. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor.

44. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.

45. Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.

46. Investigating the binding mechanism of (4-Cyanophenyl)glycine derivatives as reversible LSD1 by 3D-QSAR, molecular docking and molecular dynamics simulations.

47. JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression.

48. Critical role of histone demethylase Jumonji domain-containing protein 3 in the regulation of neointima formation following vascular injury.

49. Drug Design Concepts for LSD1‐Selective Inhibitors.

50. LSD1 (KDM1A)‐independent effects of the LSD1 inhibitor SP2509 in cancer cells.

Catalog

Books, media, physical & digital resources